Sequestration Threatens Life Sciences, Drug Development - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sequestration Threatens Life Sciences, Drug Development



Barring a last-minute deal by the US Congress to delay or end the threat of sequestration, a total of $85 billion in across-the-board U.S. government spending cuts will be triggered on March 1, threatening to slow scientific research, the development of innovative drugs and medical devices, and the ability of patients to get access to new therapies, reports Burrill & Company in a press statement.

How big an impact sequestration has on the life sciences will depend on whether action is eventually taken that spares the U.S. Food and Drug Administration and the National Institutes of Health from the cuts, and if not, how these agencies take steps to implement the cuts to their individual budgets, the statement reports.

The FDA is expected to lose $318 million in funding and cut hundreds of jobs to adjust to the lower funding level. For the NIH, sequestration would mean the loss of more than $1.6 billion in funding and reduce the number of grants it issues by more than 2,000, Burrill reports.

“While the political parties remain divided over issues of what mix of spending cuts and taxes are needed to address the country’s budget problems, it appears no one wants to take responsibility for unpopular choices and so we end up with an ax, rather than a scalpel,” says G. Steven Burrill, CEO of Burrill & Company. “The unwillingness to make difficult decisions and reach compromise will harm innovation, weaken our economic strength, and delay patients’ access to new medicines.”

The evolving situation in Washington comes against a backdrop of weakened financing activity for the life sciences sector in February, a month in which activity fell dramatically from levels a year ago. Global venture financings for life sciences companies totaled $582 million in February, a 47% decline from the same period a year ago and the lowest monthly activity in two years. On the public financing side, total global financing transactions for life sciences companies in February reached an anemic $865 million, a 78% drop from the $3.9 billion for the same period a year ago.

In addition to the sequestration drama, the threat of a government shut down looms, unless action is taken to address the current spending bill that is set to expire March 27.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What is the single greatest threat to maintaining manufacturing processes at your facility?
Quality issues
Facility/environment problems
Process development problems
Production equipment downtime
Raw material supply problems
Regulatory restrictions
Business decisions to limit production
Quality issues
42%
Facility/environment problems
0%
Process development problems
8%
Production equipment downtime
8%
Raw material supply problems
25%
Regulatory restrictions
0%
Business decisions to limit production
17%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Patent Settlements Become More Risky
Praise and Perils for Biotechnology Patent Policy
Risk-Mitigation Strategies in Drug Manufacturing for Emerging Markets
Quality Focus: Ensuring Raw Material Transparency
Advertising of Prescription Drugs  Keeping it Honest and Balanced

Click here